Cutting-Edge Updates in Cardiac Amyloidosis: What’s New for Patients

Join our expert faculty to hear about newly-approved drug therapy for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

- - - - -
Faculty: Michelle M. Kittleson, MD, PhD
Faculty: Ahmad Masri, MD, MS
- - - - -

Earn free 0.50 AMA PRA Category 1 Credit™. Access for credit will be shared at the end of this live event.

Click the link to view the Accreditation and Disclosure details before participating: Medscape.org/viewarticle/1001970.

Supported by an independent educational grant from BridgeBio.